Amgen Inc.

Other

Kenneth William Walker

Leslie Phillip Miranda

Agnes Eva Hamburger

Zhulun Wang

Colin Victor Gegg, Jr

Colin V Gegg

YuMei Xiong

Gunasekaran Kannan

Shaw-Fen Sylvia Hu

Taruna Arora

Frederick W Jacobsen

Murielle M Veniant-Ellison

John Kevin Sullivan

Hung Q Nguyen

Joseph G McGivern

Yue-Sheng Li

Jackie Zeqi Sheng

Yi Lin Zhang

Fei Xiong

Xiaoshan Min

Jie Tang

Grant Shimamoto

Thomas Charles Boone

Jane Talvenheimo

HoSung Min

Francis Hall Martin

Derek Evan Piper

Bryan D Lemon

Neeraj Jagdish Agrawal

Cen Xu

Kevin Graham

Beverly S Adler

Christopher Mohr

Taruna Arora Khare

Jeonghoon Sun

Hosung Min

Edward John Belouski

Mei-Mei Tsai

Jerry Ryan Holder

David J Lloyd

Yi Zhang

George Doellgast

Marissa Mock

Stefan I McDonough

Shu-Chen Lu

Jing Xu

Francesco Galimi

Murielle Marie Veniant Ellison

Mark Leo Michaels

Hailing Hsu

Jing M Xu

Olaf B Kinstler

Randy Ira Hecht

Karen C Sitney

Murielle Marie Ellison

Derin C D'amico

Shanaka Stanislaus

Marie E Wright

Michelle Hortter

Eileen J Johnson

Ho-Sung Min

Yumei Xiong

George (deceased) Doellgast

Murielle M Ellison

Jr Colin V Gegg

Method of treating metabolic diseases and disorders using a composition comprising a GLP-V/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins

The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein.

Transthyretin immunoglobulin fusions

GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

Growth differentiation factor 15 fusion proteins

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) polypeptides

Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

Modified Fc molecules

Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof

The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-&#x3b1;. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-&#x3b1;. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-&#x3b1; antigen binding proteins, and pharmaceutical formulations thereof.

Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof

Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Growth differentiation factor 15 (GDF-15) constructs

PAC1 antibodies and uses thereof

Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.

Carrier immunoglobulins

Growing community of inventors

Newbury Park, CA, United States of America

Kenneth William Walker